Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ROP vs DHR vs TMO vs VRSK vs MSCI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ROP
Roper Technologies, Inc.

Industrial - Machinery

IndustrialsNASDAQ • US
Market Cap$36.28B
5Y Perf.-10.5%
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$124.33B
5Y Perf.+18.9%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$176.36B
5Y Perf.+35.9%
VRSK
Verisk Analytics, Inc.

Consulting Services

IndustrialsNASDAQ • US
Market Cap$22.89B
5Y Perf.+1.2%
MSCI
MSCI Inc.

Financial - Data & Stock Exchanges

Financial ServicesNYSE • US
Market Cap$42.83B
5Y Perf.+78.9%

ROP vs DHR vs TMO vs VRSK vs MSCI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ROP logoROP
DHR logoDHR
TMO logoTMO
VRSK logoVRSK
MSCI logoMSCI
IndustryIndustrial - MachineryMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchConsulting ServicesFinancial - Data & Stock Exchanges
Market Cap$36.28B$124.33B$176.36B$22.89B$42.83B
Revenue (TTM)$8.12B$24.78B$45.20B$3.10B$3.13B
Net Income (TTM)$1.71B$3.69B$6.86B$910M$1.32B
Gross Margin69.4%60.7%39.4%67.4%82.4%
Operating Margin28.1%21.0%17.8%44.9%54.7%
Forward P/E16.1x20.8x19.1x22.9x30.0x
Total Debt$9.30B$18.42B$40.85B$5.04B$6.31B
Cash & Equiv.$297M$4.62B$9.86B$2.18B$515M

ROP vs DHR vs TMO vs VRSK vs MSCILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ROP
DHR
TMO
VRSK
MSCI
StockMay 20May 26Return
Roper Technologies,… (ROP)10089.5-10.5%
Danaher Corporation (DHR)100118.9+18.9%
Thermo Fisher Scien… (TMO)100135.9+35.9%
Verisk Analytics, I… (VRSK)100101.2+1.2%
MSCI Inc. (MSCI)100178.9+78.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: ROP vs DHR vs TMO vs VRSK vs MSCI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ROP and MSCI are tied at the top with 3 categories each (5-stock set) — the right choice depends on your priorities. MSCI Inc. is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. TMO also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
ROP
Roper Technologies, Inc.
The Growth Play

ROP carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 12.3%, EPS growth -1.0%, 3Y rev CAGR 13.7%
  • Lower volatility, beta 0.43, Low D/E 46.8%, current ratio 0.52x
  • PEG 1.68 vs DHR's 34.35
  • 12.3% revenue growth vs DHR's 2.9%
Best for: growth exposure and sleep-well-at-night
DHR
Danaher Corporation
The Quality Angle

DHR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
TMO
Thermo Fisher Scientific Inc.
The Momentum Pick

TMO ranks third and is worth considering specifically for momentum.

  • +16.8% vs VRSK's -43.0%
Best for: momentum
VRSK
Verisk Analytics, Inc.
The Lower-Volatility Pick

Among these 5 stocks, VRSK doesn't own a clear edge in any measured category.

Best for: industrials exposure
MSCI
MSCI Inc.
The Banking Pick

MSCI is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 11 yrs, beta 0.61, yield 1.2%
  • 7.2% 10Y total return vs TMO's 229.1%
  • Beta 0.61, yield 1.2%, current ratio 0.90x
  • 38.4% margin vs DHR's 14.9%
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthROP logoROP12.3% revenue growth vs DHR's 2.9%
ValueROP logoROPLower P/E (16.1x vs 30.0x), PEG 1.68 vs 1.77
Quality / MarginsMSCI logoMSCI38.4% margin vs DHR's 14.9%
Stability / SafetyROP logoROPBeta 0.43 vs TMO's 1.10, lower leverage
DividendsMSCI logoMSCI1.2% yield, 11-year raise streak, vs ROP's 0.9%
Momentum (1Y)TMO logoTMO+16.8% vs VRSK's -43.0%
Efficiency (ROA)MSCI logoMSCI24.0% ROA vs DHR's 4.5%, ROIC 34.9% vs 5.9%

ROP vs DHR vs TMO vs VRSK vs MSCI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ROPRoper Technologies, Inc.
FY 2025
Software And Related Services
100.0%$12.3B
DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
VRSKVerisk Analytics, Inc.
FY 2025
Insurance
100.0%$2.2B
MSCIMSCI Inc.
FY 2025
Index
64.3%$1.8B
Analytics
25.7%$714M
All Other Segments
10.0%$279M

ROP vs DHR vs TMO vs VRSK vs MSCI — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMSCILAGGINGVRSK

Income & Cash Flow (Last 12 Months)

MSCI leads this category, winning 4 of 6 comparable metrics.

TMO is the larger business by revenue, generating $45.2B annually — 14.6x VRSK's $3.1B. MSCI is the more profitable business, keeping 38.4% of every revenue dollar as net income compared to DHR's 14.9%. On growth, ROP holds the edge at +11.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricROP logoROPRoper Technologie…DHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…VRSK logoVRSKVerisk Analytics,…MSCI logoMSCIMSCI Inc.
RevenueTrailing 12 months$8.1B$24.8B$45.2B$3.1B$3.1B
EBITDAEarnings before interest/tax$3.2B$7.2B$10.5B$1.7B$2.0B
Net IncomeAfter-tax profit$1.7B$3.7B$6.9B$910M$1.3B
Free Cash FlowCash after capex$2.6B$5.3B$6.7B$1.1B$1.5B
Gross MarginGross profit ÷ Revenue+69.4%+60.7%+39.4%+67.4%+82.4%
Operating MarginEBIT ÷ Revenue+28.1%+21.0%+17.8%+44.9%+54.7%
Net MarginNet income ÷ Revenue+21.1%+14.9%+15.2%+29.3%+38.4%
FCF MarginFCF ÷ Revenue+31.4%+21.4%+14.9%+36.3%+49.4%
Rev. Growth (YoY)Latest quarter vs prior year+11.3%+3.7%+6.2%+3.9%
EPS Growth (YoY)Latest quarter vs prior year+59.1%+9.8%+11.3%+4.8%+49.1%
MSCI leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ROP leads this category, winning 5 of 7 comparable metrics.

At 24.8x trailing earnings, ROP trades at a 34% valuation discount to MSCI's 37.8x P/E. Adjusting for growth (PEG ratio), MSCI offers better value at 2.23x vs DHR's 34.35x — a lower PEG means you pay less per unit of expected earnings growth.

MetricROP logoROPRoper Technologie…DHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…VRSK logoVRSKVerisk Analytics,…MSCI logoMSCIMSCI Inc.
Market CapShares × price$36.3B$124.3B$176.4B$22.9B$42.8B
Enterprise ValueMkt cap + debt − cash$45.3B$138.1B$207.4B$25.7B$48.6B
Trailing P/EPrice ÷ TTM EPS24.82x34.85x26.75x26.92x37.81x
Forward P/EPrice ÷ next-FY EPS est.16.08x20.82x19.11x22.85x29.99x
PEG RatioP/E ÷ EPS growth rate2.59x34.35x12.67x3.16x2.23x
EV / EBITDAEnterprise value multiple14.57x18.21x19.04x15.34x25.17x
Price / SalesMarket cap ÷ Revenue4.59x5.06x3.96x7.45x13.67x
Price / BookPrice ÷ Book value/share1.91x2.38x3.34x78.44x
Price / FCFMarket cap ÷ FCF14.55x23.64x28.02x19.20x27.65x
ROP leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

MSCI leads this category, winning 4 of 9 comparable metrics.

VRSK delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRSK's 16.26x. On the Piotroski fundamental quality scale (0–9), MSCI scores 8/9 vs VRSK's 5/9, reflecting strong financial health.

MetricROP logoROPRoper Technologie…DHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…VRSK logoVRSKVerisk Analytics,…MSCI logoMSCIMSCI Inc.
ROE (TTM)Return on equity+8.8%+7.1%+13.2%+4.4%
ROA (TTM)Return on assets+5.0%+4.5%+6.4%+16.7%+24.0%
ROICReturn on invested capital+6.1%+5.9%+7.5%+33.0%+34.9%
ROCEReturn on capital employed+7.7%+7.0%+9.1%+39.6%+44.3%
Piotroski ScoreFundamental quality 0–967658
Debt / EquityFinancial leverage0.47x0.35x0.76x16.26x
Net DebtTotal debt minus cash$9.0B$13.8B$31.0B$2.9B$5.8B
Cash & Equiv.Liquid assets$297M$4.6B$9.9B$2.2B$515M
Total DebtShort + long-term debt$9.3B$18.4B$40.9B$5.0B$6.3B
Interest CoverageEBIT ÷ Interest expense6.50x18.13x5.89x7.87x7.67x
MSCI leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MSCI leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in MSCI five years ago would be worth $12,792 today (with dividends reinvested), compared to $7,893 for DHR. Over the past 12 months, TMO leads with a +16.8% total return vs VRSK's -43.0%. The 3-year compound annual growth rate (CAGR) favors MSCI at 8.7% vs ROP's -7.6% — a key indicator of consistent wealth creation.

MetricROP logoROPRoper Technologie…DHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…VRSK logoVRSKVerisk Analytics,…MSCI logoMSCIMSCI Inc.
YTD ReturnYear-to-date-18.5%-23.6%-19.8%-20.7%+4.5%
1-Year ReturnPast 12 months-38.0%-8.3%+16.8%-43.0%+7.8%
3-Year ReturnCumulative with dividends-21.0%-15.5%-11.7%-14.5%+28.6%
5-Year ReturnCumulative with dividends-17.5%-21.1%+2.8%+1.8%+27.9%
10-Year ReturnCumulative with dividends+115.0%+219.3%+229.1%+137.1%+720.9%
CAGR (3Y)Annualised 3-year return-7.6%-5.5%-4.0%-5.1%+8.7%
MSCI leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — VRSK and MSCI each lead in 1 of 2 comparable metrics.

VRSK is the less volatile stock with a -0.04 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MSCI currently trades 93.9% from its 52-week high vs VRSK's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricROP logoROPRoper Technologie…DHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…VRSK logoVRSKVerisk Analytics,…MSCI logoMSCIMSCI Inc.
Beta (5Y)Sensitivity to S&P 5000.43x0.94x1.10x-0.04x0.61x
52-Week HighHighest price in past year$584.03$242.80$643.99$322.92$626.28
52-Week LowLowest price in past year$313.86$172.06$385.46$161.70$501.08
% of 52W HighCurrent price vs 52-week peak+60.3%+72.3%+73.7%+54.1%+93.9%
RSI (14)Momentum oscillator 0–10043.633.043.139.554.6
Avg Volume (50D)Average daily shares traded1.2M4.2M1.9M1.9M520K
Evenly matched — VRSK and MSCI each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — ROP and MSCI each lead in 1 of 2 comparable metrics.

Analyst consensus: ROP as "Buy", DHR as "Buy", TMO as "Buy", VRSK as "Hold", MSCI as "Buy". Consensus price targets imply 40.6% upside for DHR (target: $247) vs 14.6% for MSCI (target: $674). For income investors, MSCI offers the higher dividend yield at 1.22% vs TMO's 0.36%.

MetricROP logoROPRoper Technologie…DHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…VRSK logoVRSKVerisk Analytics,…MSCI logoMSCIMSCI Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$457.64$247.00$654.67$231.25$674.33
# AnalystsCovering analysts2342422527
Dividend YieldAnnual dividend ÷ price+0.9%+0.7%+0.4%+1.0%+1.2%
Dividend StreakConsecutive years of raises1218711
Dividend / ShareAnnual DPS$3.29$1.23$1.69$1.81$7.20
Buyback YieldShare repurchases ÷ mkt cap+1.4%+2.5%+1.7%+2.7%+5.8%
Evenly matched — ROP and MSCI each lead in 1 of 2 comparable metrics.
Key Takeaway

MSCI leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ROP leads in 1 (Valuation Metrics). 2 tied.

Best OverallMSCI Inc. (MSCI)Leads 3 of 6 categories
Loading custom metrics...

ROP vs DHR vs TMO vs VRSK vs MSCI: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ROP or DHR or TMO or VRSK or MSCI a better buy right now?

For growth investors, Roper Technologies, Inc.

(ROP) is the stronger pick with 12. 3% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Roper Technologies, Inc. (ROP) offers the better valuation at 24. 8x trailing P/E (16. 1x forward), making it the more compelling value choice. Analysts rate Roper Technologies, Inc. (ROP) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ROP or DHR or TMO or VRSK or MSCI?

On trailing P/E, Roper Technologies, Inc.

(ROP) is the cheapest at 24. 8x versus MSCI Inc. at 37. 8x. On forward P/E, Roper Technologies, Inc. is actually cheaper at 16. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Roper Technologies, Inc. wins at 1. 68x versus Danaher Corporation's 34. 35x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — ROP or DHR or TMO or VRSK or MSCI?

Over the past 5 years, MSCI Inc.

(MSCI) delivered a total return of +27. 9%, compared to -21. 1% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: MSCI returned +720. 9% versus ROP's +115. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ROP or DHR or TMO or VRSK or MSCI?

By beta (market sensitivity over 5 years), Verisk Analytics, Inc.

(VRSK) is the lower-risk stock at -0. 04β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately -3152% more volatile than VRSK relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 16% for Verisk Analytics, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ROP or DHR or TMO or VRSK or MSCI?

By revenue growth (latest reported year), Roper Technologies, Inc.

(ROP) is pulling ahead at 12. 3% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: MSCI Inc. grew EPS 10. 7% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, ROP leads at 13. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ROP or DHR or TMO or VRSK or MSCI?

MSCI Inc.

(MSCI) is the more profitable company, earning 38. 4% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 38. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MSCI leads at 54. 7% versus 18. 2% for TMO. At the gross margin level — before operating expenses — MSCI leads at 82. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ROP or DHR or TMO or VRSK or MSCI more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Roper Technologies, Inc. (ROP) is the more undervalued stock at a PEG of 1. 68x versus Danaher Corporation's 34. 35x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Roper Technologies, Inc. (ROP) trades at 16. 1x forward P/E versus 30. 0x for MSCI Inc. — 13. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 40. 6% to $247. 00.

08

Which pays a better dividend — ROP or DHR or TMO or VRSK or MSCI?

All stocks in this comparison pay dividends.

MSCI Inc. (MSCI) offers the highest yield at 1. 2%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).

09

Is ROP or DHR or TMO or VRSK or MSCI better for a retirement portfolio?

For long-horizon retirement investors, Verisk Analytics, Inc.

(VRSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 04), 1. 0% yield, +137. 1% 10Y return). Both have compounded well over 10 years (VRSK: +137. 1%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ROP and DHR and TMO and VRSK and MSCI?

These companies operate in different sectors (ROP (Industrials) and DHR (Healthcare) and TMO (Healthcare) and VRSK (Industrials) and MSCI (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

ROP, DHR, VRSK, MSCI pay a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ROP

Quality Mega-Cap Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 12%
Run This Screen
Stocks Like

DHR

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 8%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

TMO

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 9%
Run This Screen
Stocks Like

VRSK

Quality Mega-Cap Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Net Margin > 17%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

MSCI

Quality Mega-Cap Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 23%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ROP and DHR and TMO and VRSK and MSCI on the metrics below

Revenue Growth>
%
(ROP: 11.3% · DHR: 3.7%)
Net Margin>
%
(ROP: 21.1% · DHR: 14.9%)
P/E Ratio<
x
(ROP: 24.8x · DHR: 34.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.